Investors

Bioasis Technologies, Inc. is a science-driven company focused on revolutionizing science by transporting therapeutic payloads across the blood-brain barrier and into the brain. Our goal is to generate shareholder value by developing and commercializing our proprietary brain delivery technology, xB3, to make life-saving drugs brain-penetrant and deliver those drugs at a therapeutically relevant dose.

All Public Filings (Canada)

Most Recent Financial Reports (US)

Corporate Presentation

Stock Quote

Investor News and Events

  • Mar. 8, 2021 Bioasis to Attend and Present at Upcoming Investor and Industry Conferences

    NEW HAVEN, Conn., March 08, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical… Read more »

  • Jan. 27, 2021 Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2020

    GUILFORD, Conn., Jan. 27, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies Inc.?(TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”),?a?pre-clinical, research-stage?biopharmaceutical company developing its proprietary?xB3 TM?platform?technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases,?today announced… Read more »

  • Jan. 4, 2021 Bioasis to Present at Upcoming Industry Conferences

    GUILFORD, Conn., Jan. 04, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. – Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high… Read more »

All Events and Presentations